Dr. Kallam Anji Reddy: How He Transformed the Indian Pharmaceutical Industry

Major Events Of Anji Reddy’s Life

  • 1984: Dr. Anji Reddy founded Dr. Reddy’s Laboratories in Hyderabad, India. The company started as a small pharmaceutical company with a focus on research and development.
  • 1986: Dr. Reddy’s Laboratories began manufacturing and marketing bulk drugs.
  • 1987: The company began exporting pharmaceuticals to the United States and Europe.
  • 1991: Dr. Reddy’s Laboratories went public and listed on the Bombay Stock Exchange.
  • 1993: The company launched its first generic drug, cimetidine, in the United States.
  • 1996: Dr. Reddy’s Laboratories became the first Indian company to receive a US FDA approval for a new drug application.
  • 1998: The company entered into a partnership with Merck & Co. to market and distribute its products in the United States.
  • 2001: Dr. Reddy’s Laboratories acquired American Remedies, an American pharmaceutical company.
  • 2003: The company acquired Betapharm, a German generic drug maker.
  • 2006: Dr. Reddy’s Laboratories acquired Roche’s API manufacturing plant in Mexico.
  • 2007: The company acquired a majority stake in Cheminor Drugs, an Indian API manufacturer.
  • 2011: Dr. Reddy’s Laboratories acquired GlaxoSmithKline’s oral penicillin manufacturing facility in Bristol, Tennessee.
  • 2012: The company acquired Netherlands-based OctoPlus NV, a drug delivery technology company.
  • 2014: Dr. Reddy’s Laboratories launched its biosimilars business.
  • 2015: The company acquired the US-based generic drug maker, Ranbaxy Laboratories, for $3.2 billion.
  • 2016: Dr. Reddy’s Laboratories announced that it had received a warning letter from the US FDA regarding its API manufacturing plant in Andhra Pradesh, India.
  • 2017: The company announced the launch of its biosimilar version of Roche’s breast cancer drug, Herceptin, in India.
  • 2018: Dr. Reddy’s Laboratories received approval from the US FDA for its generic version of Suboxone, a drug used to treat opioid addiction.
  • 2019: The company announced that it had received a warning letter from the US FDA regarding its formulations manufacturing plant in Telangana, India.
  • 2020: Dr. Reddy’s Laboratories announced that it had entered into a partnership with Russia’s sovereign wealth fund to conduct clinical trials and distribute Sputnik V, a COVID-19 vaccine developed in Russia.
  • Present: Dr. Reddy’s Laboratories continues to be a leading pharmaceutical company in India, with a strong focus on research and development, generic drugs, biosimilars, and drug delivery technologies. The company has a global presence and is a major player in the US and European pharmaceutical markets.

Dr. Kallam Anji Reddy was an Indian entrepreneur and philanthropist who is best known as the founder of Dr. Reddy’s Laboratories, one of India’s largest pharmaceutical companies. Anji Reddy was a visionary entrepreneur who believed in the power of research and innovation to transform the pharmaceutical industry.